ArticleHeliyon2024

Alemtuzumab infusion-associated reactions and laboratory changes in patients with relapsing-remitting multiple sclerosis at baseline and first-year follow-up.

Furkan Saridas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.